Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Benzinga · 08/03 21:28
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.